GLP-1 Drugs Prevent Heart Attack Damage

A new study co-led by the University of Bristol and University College London has found that GLP-1 mimicking drugs, commonly used for weight loss and diabetes, may prevent further tissue damage after a heart attack. These drugs could significantly reduce the risk of 'no-reflow,' a complication where tiny blood vessels in the heart remain narrowed even after the main artery is cleared, affecting up to half of all heart attack patients. The research, published in Nature Communications and funded by the British Heart Foundation, suggests that GLP-1 drugs improve blood flow by activating potassium channels and relaxing pericytes, allowing constricted blood vessels to dilate. This breakthrough highlights the potential to repurpose existing drugs like Novo Nordisk===Semaglutide and Novo Nordisk===Semaglutide, offering a promising new therapeutic approach for improving heart attack recovery and potentially saving lives. Further clinical trials in humans are needed to confirm these findings.